Weekly-Round-Up-February 13th to February 19th
February 21, 2023
Cerevance, a privately held, clinical-stage drug discovery and development business, announced an expansion of its Series B investment round with an additional closing of $51 million, bringing the total Series B financing to $116 million. The firm is focused on discovering innovative therapies for central nervous system (CNS) illnesses using the company’s patented Nuclear Enriched Transcript Sort sequencing (NETSseq) platform. The funding will be utilized for planned clinical trials for Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
Juniper Square, a prominent provider of relationship enablement services to the private funds industry, has secured $133 million in growth capital. Owl Rock, a division of Blue Owl, led the investment, with contributions from current investors Ribbit Capital, Redpoint Ventures, and Felicis Ventures, as well as new investors Fifth Wall and Pappy Capital.
Checkerspot, a biotechnology firm with an award-winning design and innovation studio, has closed a $55 million Series C investment round. ArrowMark Partners led the investment, with Cox Enterprises and other new and current investors joining. Checkerspot was advised by Allen & Company LLC on the deal. Checkerspot’s development and commercialization of high-performance, biobased alternatives for everyday products will be accelerated due to the funding.
Get Spiffy, Inc. (Spiffy), an on-demand car care, technology, and services company, announced the completion of its Series C financing round, raising $30 million to fuel Spiffy’s Digital Servicing private-label hardware and software-as-a-service offering for automotive dealers. Edison Partners led the investment, with current investors Tribeca Venture Partners, Bull City Venture Partners, IDEA Fund Partners, Trog Hawley Capital, Attinger, Private Access Network, and strategic investors Shell Ventures, Goodyear Ventures, and Mann+Hummel also participating. Spiffy’s exclusive advisor on the round was The Presidio Group.
Codagenix Inc., a clinical-stage synthetic biology firm with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapies, announced the completion of a $25 million Series B extension fundraising, with participation from a new investor, the Serum Institute of India Pvt. Ltd.
R-Zero, a global pioneer in healthy and green buildings, announced the completion of a $105 million Series C round to accelerate the adoption of its UV-C technology to address a rising health crisis: cleaning the indoor air we breathe.BMO Financial Group, Qualcomm Ventures, and Upfront Ventures are among the new investors, as are DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, and John Doerr.
Avilar Therapeutics, a biopharmaceutical business focused on extracellular protein degradation, announced that it has acquired additional funding from a larger syndicate of new investors to support the advancement of a pipeline of first-in-class extracellular protein degraders. The additional funding represents an increase to $75 million from the seed round, which was first funded by Avilar’s founding investor, RA Capital Management, and now includes new investors Sanofi Ventures, Medical Excellence Capital (MEC), and Astellas Venture Management (AVM).
Zerocater, the quick supplier of corporate cafeterias and catering solutions, has raised $15 million in Series C funding headed by Cleveland Avenue LLC, with Remus Capital participating. The company has announced that it would expand its technology-enabled corporate cafeteria solution to ten new areas, including its first foreign market in Canada.
Related Links:
Weekly Round-Up – Feb 6 to Feb 12
Weekly Round-Up – Jan 30 to Feb 5
